AU753014B2 - Dry powder active agent pulmonary delivery - Google Patents

Dry powder active agent pulmonary delivery Download PDF

Info

Publication number
AU753014B2
AU753014B2 AU60397/99A AU6039799A AU753014B2 AU 753014 B2 AU753014 B2 AU 753014B2 AU 60397/99 A AU60397/99 A AU 60397/99A AU 6039799 A AU6039799 A AU 6039799A AU 753014 B2 AU753014 B2 AU 753014B2
Authority
AU
Australia
Prior art keywords
particles
active agent
cyclodextrin
growth inhibitor
hygroscopic growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU60397/99A
Other languages
English (en)
Other versions
AU6039799A (en
Inventor
Barry John Aldous
Andrew Clark
Mei-Chang Kuo
Cecily Lalor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Inhale Therapeutics Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutics Systems Inc filed Critical Inhale Therapeutics Systems Inc
Publication of AU6039799A publication Critical patent/AU6039799A/en
Application granted granted Critical
Publication of AU753014B2 publication Critical patent/AU753014B2/en
Assigned to NEKTAR THERAPEUTICS reassignment NEKTAR THERAPEUTICS Alteration of Name(s) in Register under S187 Assignors: INHALE THERAPEUTIC SYSTEMS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AU60397/99A 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery Ceased AU753014B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14
US60/100163 1998-09-14
PCT/US1999/021109 WO2000015262A1 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Publications (2)

Publication Number Publication Date
AU6039799A AU6039799A (en) 2000-04-03
AU753014B2 true AU753014B2 (en) 2002-10-03

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60397/99A Ceased AU753014B2 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Country Status (44)

Country Link
EP (1) EP1117442A1 (hu)
JP (1) JP2002524535A (hu)
KR (1) KR20010075063A (hu)
CN (1) CN1317977A (hu)
AP (1) AP1374A (hu)
AR (1) AR022090A1 (hu)
AU (1) AU753014B2 (hu)
BG (1) BG105430A (hu)
BR (1) BR9913722A (hu)
CA (1) CA2343920A1 (hu)
CO (1) CO5130023A1 (hu)
CZ (1) CZ2001829A3 (hu)
DZ (1) DZ2892A1 (hu)
EA (1) EA003476B1 (hu)
EE (1) EE200100151A (hu)
GE (1) GEP20043257B (hu)
GT (1) GT199900156A (hu)
HK (1) HK1042231A1 (hu)
HN (1) HN1999000159A (hu)
HR (1) HRP20010189A2 (hu)
HU (1) HUP0103837A3 (hu)
ID (1) ID28845A (hu)
IL (2) IL141562A0 (hu)
IS (1) IS5878A (hu)
LT (1) LT4897B (hu)
LV (1) LV12658B (hu)
MA (1) MA25590A1 (hu)
MY (1) MY129282A (hu)
NO (1) NO20011251L (hu)
NZ (1) NZ510168A (hu)
OA (1) OA11781A (hu)
PA (1) PA8481901A1 (hu)
PE (1) PE20001061A1 (hu)
PL (1) PL195574B1 (hu)
SA (1) SA99200718B1 (hu)
SK (1) SK3442001A3 (hu)
TN (1) TNSN99173A1 (hu)
TR (1) TR200101182T2 (hu)
TW (1) TWI226248B (hu)
UA (1) UA76085C2 (hu)
UY (1) UY25711A1 (hu)
WO (1) WO2000015262A1 (hu)
YU (1) YU24201A (hu)
ZA (1) ZA200101995B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2005518453A (ja) 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
EP1539246A4 (en) * 2002-07-03 2007-05-16 Brigham & Womens Hospital ADMINISTRATION IN THE CENTRAL AIRWAYS FOR THE SYSTEMIC DELIVERY OF THERAPEUTICS
BR0317392A (pt) * 2002-12-19 2005-12-20 Pharmacia Corp Formulação não-higroscópica incluindo uma droga higroscópica
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MXPA06012240A (es) * 2004-04-23 2007-01-31 Cydex Inc Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1857114A1 (en) * 2005-03-09 2007-11-21 Ono Pharmaceutical Co., Ltd. Particle and preparation containing the particle
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PT2583668E (pt) 2005-10-26 2015-01-05 Cydex Pharmaceuticals Inc Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
CN101541311B (zh) * 2006-10-25 2013-01-23 大日本住友制药株式会社 不易结块的颗粒制剂
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
BRPI0818119A2 (pt) 2007-10-31 2015-08-04 Diffusion Pharmaceuticals Llc Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
BR112014026957A8 (pt) * 2012-05-03 2018-01-16 Janssen R&D Ireland micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611567A1 (en) * 1992-06-12 1994-08-24 Teijin Limited Ultrafine powder for inhalation and production thereof
WO1996019197A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol formulations of peptides and proteins
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611567A1 (en) * 1992-06-12 1994-08-24 Teijin Limited Ultrafine powder for inhalation and production thereof
WO1996019197A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol formulations of peptides and proteins
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation

Also Published As

Publication number Publication date
KR20010075063A (ko) 2001-08-09
BR9913722A (pt) 2001-05-29
NO20011251L (no) 2001-04-17
HRP20010189A2 (en) 2005-04-30
PL346768A1 (en) 2002-02-25
GT199900156A (es) 2001-03-07
AR022090A1 (es) 2002-09-04
CO5130023A1 (es) 2002-02-27
LT2001021A (en) 2001-11-26
OA11781A (en) 2005-07-26
DZ2892A1 (fr) 2003-12-15
EP1117442A1 (en) 2001-07-25
HUP0103837A3 (en) 2002-11-28
WO2000015262A1 (en) 2000-03-23
HK1042231A1 (zh) 2002-08-09
PA8481901A1 (es) 2002-04-25
MA25590A1 (fr) 2002-12-31
EA003476B1 (ru) 2003-06-26
NO20011251D0 (no) 2001-03-13
LV12658A (lv) 2001-05-20
CZ2001829A3 (cs) 2001-09-12
YU24201A (sh) 2003-08-29
TNSN99173A1 (fr) 2005-11-10
JP2002524535A (ja) 2002-08-06
TWI226248B (en) 2005-01-11
ZA200101995B (en) 2002-03-11
NZ510168A (en) 2003-09-26
IL141562A0 (en) 2002-03-10
IL141562A (en) 2007-07-24
BG105430A (en) 2001-12-29
SK3442001A3 (en) 2001-11-06
ID28845A (id) 2001-07-05
AP2001002093A0 (en) 2001-03-31
UA76085C2 (en) 2006-07-17
PL195574B1 (pl) 2007-10-31
LT4897B (lt) 2002-02-25
EE200100151A (et) 2002-06-17
HUP0103837A2 (hu) 2002-05-29
SA99200718B1 (ar) 2006-11-04
LV12658B (lv) 2001-09-20
CA2343920A1 (en) 2000-03-23
AU6039799A (en) 2000-04-03
MY129282A (en) 2007-03-30
AP1374A (en) 2005-02-28
GEP20043257B (en) 2004-06-25
UY25711A1 (es) 1999-11-17
CN1317977A (zh) 2001-10-17
EA200100300A1 (ru) 2001-10-22
TR200101182T2 (tr) 2001-09-21
HN1999000159A (es) 1999-11-11
IS5878A (is) 2001-03-05
PE20001061A1 (es) 2000-10-08

Similar Documents

Publication Publication Date Title
AU753014B2 (en) Dry powder active agent pulmonary delivery
US5855913A (en) Particles incorporating surfactants for pulmonary drug delivery
CA2336139C (en) Large porous particles emitted from an inhaler
USRE37053E1 (en) Particles incorporating surfactants for pulmonary drug delivery
US6921528B2 (en) Highly efficient delivery of a large therapeutic mass aerosol
JP4859320B2 (ja) 改良された分散性を有する乾燥粉末組成物
CA2432175C (en) Storage stable powder compositions of interleukin-4 receptor
US6652837B1 (en) Preparation of novel particles for inhalation
Hamishehkar et al. The role of carrier in dry powder inhaler
JP2003513031A5 (hu)
NZ530123A (en) Particles comprising DPPC, insulin, sodium citrate and optionally an amino acid in a composition for inhalation that has rapid release properties
US20040009231A1 (en) hGH (human growth hormone) formulations for pulmonary administration
MXPA01002649A (en) Dry powder active agent pulmonary delivery
Batycky et al. The development of large porous particles for inhalation drug delivery
CA2403349C (en) Preparation of particles for inhalation
EP1273290A1 (en) Large porous particles emitted from an inhaler
EP1767195A2 (en) Stable spray-dried protein formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEKTAR THERAPEUTICS

Free format text: FORMER OWNER WAS: INHALE THERAPEUTIC SYSTEMS, INC.